
Mayo Clinic experimental dual-drug nanotherapy crosses the blood-brain barrier and improved survival in preclinical glioblastoma models
<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxQdVpUbUFsdXNSQ25pYWdkOTJGNFJNeWJvd3ZnU2dZX1BEY1pvQ2FiRDlaOUtjV0hKZ0ZWSFM2RjhNM3FYLUw3alVjU183WUNzenBXUFBab2FlbmFvaW1taTJrZjhRSG9JZW1QQTJEdTRFVE9ZV2Nia1drYVhjbmhfWXlwblhsUjQ5Q1AyeDlMaVNjcDk2NTBHV0hSeW9xRnBMTjR1TzdLajFmLWxtOXNiSlR6TWxObE5uVjcyeGlZeHFhdVpYY294VnRYUURuYy1MNk5KcFMzc0hJY21rd0RPZUl2ZWlsRURTa1NnZEgyQjU2VzlqUExTZTExTUoyUHZVUUVXcDBFRlVfLVB3WGFn?oc=5" target="_blank">Mayo Clinic experimental dual-drug nanotherapy crosses the blood-brain barrier and improved survival in preclinical glioblastoma models</a>&nbsp;&nbsp;<font color="#6f6f6f">Mayo Clinic News Network</font>
